Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05490511 · ClinicalTrials.gov registry record · Phase 1
Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus
A Phase 1 study of CBD and Kidney Disease, Chronic, sponsored by Indiana University.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
- 1
- Study location
NCT05490511 is a Phase 1 study of CBD and Kidney Disease, Chronic that has completed, run by Indiana University. The registered enrollment target is 57 participants, roughly in line with the 60-participant average among 8 other CBD trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT05490511, a Phase 1 study of CBD and Kidney Disease, Chronic, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
- 1
- Study location
Study Summary
The information learned in these studies will help to inform doctors as to how to appropriately adjust doses of cannabidiol and tacrolimus in order to improve health outcomes and long-term treatment success for transplant recipients.
Conditions Studied
Interventions
- DRUG Tacrolimus single dose
- DRUG Epidiolex single dose
- DRUG Epidiolex steady-state and tacrolimus single dose
Study Locations (1)
Indiana
- IU Health University Hospital - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2022-10-31 |
| Est. Completion | 2025-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05490511
The ClinicalTrials.gov registry entry for NCT05490511 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 60-participant average among 8 other CBD trials with a reported enrollment target. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with CBD appearing as the primary indexed condition, and to 3 interventions - of which Tacrolimus single dose is the first listed.
NCT05490511 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT05490511 about?
NCT05490511 is a clinical study titled "Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus". The information learned in these studies will help to inform doctors as to how to appropriately adjust doses of cannabidiol and tacrolimus in order to improve health outcomes and long-term treatment success for transplant recipients.
What is the current status of trial NCT05490511?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2022-10-31. Estimated completion is 2025-08-31.
What conditions does trial NCT05490511 study?
This clinical trial studies the following conditions: CBD, Kidney Disease, Chronic, Transplant Complication.
What interventions are being tested in trial NCT05490511?
The interventions under investigation include: Tacrolimus single dose (DRUG), Epidiolex single dose (DRUG), Epidiolex steady-state and tacrolimus single dose (DRUG).
Who is sponsoring clinical trial NCT05490511?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05490511 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CBD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Cannabidiol on Stress and Nicotine Withdrawal
RECRUITING · Phase 1
-
Hippocampal Response to Acute Oral Doses of CBD During an fMRI Memory Task
ACTIVE NOT RECRUITING · Phase 1
-
CBD-Microglia PET Study
RECRUITING · Early Phase 1
-
Cannabidiol (CBD) and Stress Response: Psychobiological Mechanisms
RECRUITING · NA
-
A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes
ACTIVE NOT RECRUITING
-
RCT of CBD for Anxiety in Advanced Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.